Dr. Maxwell Lloyd, a Medical Fellow in Drugs within the Division of Drugs at Beth Israel Deaconess Medical Heart in Boston, sat down for in interview with CURE® on the 2024 San Antonio Breast Most cancers Symposium. Within the interview, he shared insights on the long-term administration of sufferers with HR-positive, HER2-negative breast most cancers who’ve acquired Orserdu (elacestrant) therapy
“It is an evolving space, with varied therapy paradigms which might be obtainable,” Lloyd emphasised, highlighting that, as time goes on, clinicians are aiming to include extra precision-based therapeutic choices into therapy methods.
To listen to extra of Lloyd’s insights, learn his full response right here.
Transcript:
Publish-Orserdu, there are nonetheless plenty of therapy choices for sufferers with superior breast most cancers that is going to be personalised and affected person dependent. [These treatments] proceed to give attention to potential methods of precision-based therapies so as to discover the precise therapy for the precise affected person on the proper time. In regard to the post-Orserdu panorama — when it comes to genomic sequencing — we nonetheless haven’t got a strong understanding of what that may appear like in the way in which that we do after first-line endocrine remedy and CDK4/6 inhibitor. There could also be comparable targets for a focused therapeutic or mixture technique that may assist us delay the initiation of a extra normal chemotherapy.
Some sufferers might have breast most cancers that’s extra quickly progressive, much less endocrine remedy delicate. These are the oldsters that we [may consider] one thing like Enhertu [trastuzumab deruxtecan; T-DXd] if it is HER2-low or ultra-low, or a extra conventional line of chemotherapy like capitaine. It is an evolving space, with varied therapy paradigms which might be obtainable.
We have to take a look at these medical and genomic components to assist predict what sufferers are going to learn most and reduce any pointless toxicity by avoiding giving remedies to sufferers that won’t [respond well to treatment]. That is a part of an ongoing effort [which continues to] tailor remedy to the underlying biology of the affected person’s tumor with the hope to assist folks dwell longer, more healthy, extra full lives.
Transcript was edited for readability and conciseness.
For extra information on most cancers updates, analysis and training, don’t overlook to subscribe to CURE®’s newsletters right here.
